Therapeutic Strategies for Nonmelanoma Skin Cancers
Journal of the National Comprehensive Cancer Network · 2026-05 · 24 (Supplement) · 24-26
DOI: 10.6004/jnccn.2026.5007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-05. Verfasst von Vincent T. Ma. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Recent updates to the NCCN Guidelines, along with emerging clinical trial data, are refining the management of cutaneous squamous cell carcinoma (cSCC) and informing surveillance strategies in Merkel cell carcinoma (MCC). In high-risk resectable cSCC, surgery followed by radiation therapy remains the standard of care, with adjuvant cemiplimab-rwlc now approved by the FDA following definitive local treatment. Neoadjuvant cemiplimab may be considered in select patients, including those with rapidly growing or borderline resectable tumors. In MCC, active surveillance remains the standard after definitive therapy. Tumor-informed circulating tumor DNA has demonstrated sensitivity and prognostic value for recurrence detection and may identify disease prior to clinical or radiographic evidence; however, it is not yet validated to guide systemic treatment decisions.
Zitieren
APA
Ma, V. T. (2026). Therapeutic Strategies for Nonmelanoma Skin Cancers. Journal of the National Comprehensive Cancer Network, 24(Supplement), 24-26. https://doi.org/10.6004/jnccn.2026.5007
Vancouver
Ma VT. Therapeutic Strategies for Nonmelanoma Skin Cancers. Journal of the National Comprehensive Cancer Network. 2026;24(Supplement):24-26. doi:10.6004/jnccn.2026.5007
BibTeX
@article{Ma2026,
author = {Ma, Vincent T.},
title = {Therapeutic Strategies for Nonmelanoma Skin Cancers},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {Supplement},
pages = {24--26},
doi = {10.6004/jnccn.2026.5007}
}
EUVIMED